Financials data is unavailable for this security.
View more
Year on year Beijing Tongrentang Co Ltd grew revenues 16.19% from 15.37bn to 17.86bn while net income improved 16.92% from 1.43bn to 1.67bn.
Gross margin | 44.48% |
---|---|
Net profit margin | 13.33% |
Operating margin | 16.17% |
Return on assets | 7.88% |
---|---|
Return on equity | 12.63% |
Return on investment | 15.63% |
More ▼
Cash flow in CNYView more
In 2023, Beijing Tongrentang Co Ltd did not generate a significant amount of cash. However, the company earned 1.87bn from its operations for a Cash Flow Margin of 10.47%. In addition the company used 76.18m on investing activities and also paid 1.43bn in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.46 |
---|---|
Tangible book value per share | 8.87 |
More ▼
Balance sheet in CNYView more
Current ratio | 2.86 |
---|---|
Quick ratio | 1.58 |
Total debt/total equity | 0.3387 |
---|---|
Total debt/total capital | 0.1765 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 56.25% and 17.04%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
Div yield(5 year avg) | 1.09% |
---|---|
Div growth rate (5 year) | 13.97% |
Payout ratio (TTM) | 69.07% |
EPS growth(5 years) | 8.03 |
---|---|
EPS (TTM) vs TTM 1 year ago | -10.22 |
More ▼